Apellis Roe from 2010 to 2024

APLS Stock  USD 33.93  0.21  0.62%   
Apellis Pharmaceuticals ROE yearly trend continues to be comparatively stable with very little volatility. ROE will likely drop to -2.85 in 2024. From the period from 2010 to 2024, Apellis Pharmaceuticals ROE quarterly data regression had mean square error of  4.01 and mean deviation of  1.55. View All Fundamentals
 
ROE  
First Reported
2010-12-31
Previous Quarter
(2.72)
Current Value
(2.85)
Quarterly Volatility
2.222495
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 31.1 M or Selling General Administrative of 525.9 M, as well as many indicators such as Price To Sales Ratio of 33.56, Dividend Yield of 0.0 or PTB Ratio of 19.3. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Latest Apellis Pharmaceuticals' Roe Growth Pattern

Below is the plot of the Roe of Apellis Pharmaceuticals over the last few years. It is Apellis Pharmaceuticals' ROE historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Roe10 Years Trend
Slightly volatile
   Roe   
       Timeline  

Apellis Roe Regression Statistics

Arithmetic Mean(2.12)
Coefficient Of Variation(104.75)
Mean Deviation1.55
Median(1.14)
Standard Deviation2.22
Sample Variance4.94
Range8.7086
R-Value(0.50)
Mean Square Error4.01
R-Squared0.25
Significance0.06
Slope(0.25)
Total Sum of Squares69.15

Apellis Roe History

2024 -2.85
2023 -2.72
2022 -3.84
2021 -3.76
2020 -1.69
2019 -9.05
2018 -0.79

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as Roe, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
ROE(2.72)(2.85)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.